Update on: NICE Recommends New At-Home Treatment for Endometriosis

Introduction

Endometriosis is a long-term condition where tissue similar to the lining of the womb grows in other places, such as the ovaries and fallopian tubes. It affects around 1.5 million women in the UK and can cause chronic pain, fatigue, and depression. Many women experience difficulties with daily activities, work, education, and relationships due to the condition.

About the Treatment

NICE’s draft guidance recommends linzagolix (brand name Yselty), a once-daily pill that can be taken at home. It works by reducing the hormone oestrogen, which helps control the symptoms of endometriosis. The treatment is taken with hormone replacement therapy to protect bone health and manage other side effects.

Potential Impact

Up to 1,000 women a year in England could be eligible for linzagolix under this new recommendation. It offers an alternative for those who cannot have, or have not responded to, other medical or surgical treatments for endometriosis.

Statements from NICE

Helen Knight, director of medicines evaluation at NICE, said:

“Endometriosis is a painful and debilitating condition and current treatment options are limited. Linzagolix with hormone replacement therapy offers an additional oral treatment option for people with endometriosis.”

“This is the first time in over a decade that NICE has recommended a treatment for endometriosis. We are pleased to be able to do so now, as it gives women more choice in managing this often very difficult condition.”

Conclusion

The recommendation of linzagolix marks the first NICE-approved treatment for endometriosis in over ten years. If final guidance is published as planned on 25 June 2025, the NHS in England will be expected to make the treatment available within 90 days.

Citation:
National Institute for Health and Care Excellence. (2025, May 1). Up to 1,000 women a year could benefit from new at-home treatment for endometriosis. NICE.